Announcements Trials
Browse Landscape

Phase

Phase 3 8Phase 2 6Phase 1/2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 45Neoplasms 26Colorectal Neoplasms 24Neoplasm Metastasis 22Recurrence 21Ovarian Neoplasms 21Pancreatic Neoplasms 20Breast Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Melanoma 16Glioblastoma 15Prostatic Neoplasms 14Lymphoma, Large B-Cell, Diffuse 13Endometrial Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Multiple Myeloma 12Lymphoma, Non-Hodgkin 12Triple Negative Breast Neoplasms 11Lung Neoplasms 11Glioma 10Colonic Neoplasms 10Carcinoma, Renal Cell 10Stomach Neoplasms 9Rectal Neoplasms 9Gastrointestinal Neoplasms 9Lymphoma, Follicular 8Lymphoma 8Leukemia, Myeloid, Acute 8Head and Neck Neoplasms 8Brain Neoplasms 8

Interventions

erdafitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Non-Muscle Invasive Bladder Neoplasms × 30 days × Clear all
NCT05316155 2026-06-05

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Janssen Research & Development, LLC

Phase 1/2 Recruiting
235 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05710848 2026-05-27

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

SURGE Therapeutics

Phase 1/2 Recruiting
75 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡